Pazopanib: a novel treatment option for aggressive fibromatosisReport as inadecuate




Pazopanib: a novel treatment option for aggressive fibromatosis - Download this document for free, or read online. Document in PDF available to download.

Clinical Sarcoma Research

, 6:22

First Online: 01 December 2016Received: 02 June 2016Accepted: 01 November 2016DOI: 10.1186-s13569-016-0061-3

Cite this article as: Bulut, G., Ozluk, A., Erdogan, A.P. et al. Clin Sarcoma Res 2016 6: 22. doi:10.1186-s13569-016-0061-3

Abstract

BackgroundAggressive fibromatosis AF, also known as desmoid tumor, is an uncommon soft tissue neoplasm. AF does not metastasize, but it is locally invasive and its propensity for recurrence after conservative resection is well documented. No effective cytotoxic treatment has been reported, hence there is a need for novel treatment strategies.

Case presentationWe present the case of an AF successfully treated with an oral tyrosine kinase inhibitor, pazopanib, with mild side effects. As far as we know, this is the first case of AF with complete response to pazopanib.

ConclusionPazopanib might be an effective treatment option for AF.

KeywordsPazopanib Aggressive fibromatosis Desmoid tumor Oral tyrosine kinase inhibitor AbbreviationsAFaggressive fibromatosis

NSAIDsnonsteroidal anti-inflammatory drugs

VEGFvascular endothelial growth factor

PDGFplatelet derivated growth factor

FDAUS Food and Drug Administration

EMAThe European Medicines Agency

CTcomputed tomography

PETpositron emission tomography

Download fulltext PDF



Author: Gulcan Bulut - Anil Ozluk - Atike Pınar Erdogan - Ruchan Uslu - Nevra Elmas - Burcak Karaca

Source: https://link.springer.com/







Related documents